PuSH - Publikationsserver des Helmholtz Zentrums München

Wahida, A. ; Buschhorn, L.* ; Fröhling, S.* ; Jost, P.J.* ; Schneeweiss, A.* ; Lichter, P.* ; Kurzrock, R.*

The coming decade in precision oncology: Six riddles.

Nat. Rev. Cancer 23, 43–54 (2023)
DOI
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
High-throughput methods to investigate tumour omic landscapes have quickly catapulted cancer specialists into the precision oncology era. The singular lesson of precision oncology might be that, for it to be precise, treatment must be personalized, as each cancer’s complex molecular and immune landscape differs from patient to patient. Transformative therapies include those that are targeted at the sequelae of molecular abnormalities or at immune mechanisms, and, increasingly, pathways previously thought to be undruggable have become druggable. Critical to applying precision medicine is the concept that the right combination of drugs must be chosen for each patient and used at the right stage of the disease. Multiple puzzles remain that complicate therapy choice, including evidence that deleterious mutations are common in normal tissues and non-malignant conditions. The host’s role is also likely to be key in determining treatment response, especially for immunotherapy. Indeed, maximizing the impact of immunotherapy will require omic analyses to match the right immune-targeted drugs to the individualized patient and tumour setting. In this Perspective, we discuss six key riddles that must be solved to optimize the application of precision oncology to otherwise lethal malignancies.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
ISSN (print) / ISBN 1474-175X
e-ISSN 1474-1768
Quellenangaben Band: 23, Heft: , Seiten: 43–54 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Begutachtungsstatus Peer reviewed
Förderungen Deutschen Konsortium für Translationale Krebsforschung
Nationales Centrum für Tumorerkrankungen Heidelberg
Torsten-Haferlach Leukaemia Diagnostics Foundation
Claudia von Schilling foundation